Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Investor Investigation Concerning Possible Securities Laws Violations Announced

If you purchased shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Taro Pharmaceutical Industries
Affected Securities: 
NYSE: TARO

October 20, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) shares over potential securities laws violations by Taro Pharmaceutical Industries and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) concerning whether a series of statements by Taro Pharmaceutical Industries regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Taro Pharmaceutical Industries Ltd. reported that its Total Revenue rose from $862.94 million for the 12 months period that ended on March 31, 2015 to $950.75 million for the 12 months period that ended on March 31, 2016 and that its Net Income for those time periods increased from $484.26 million to $540.93 million.

On September 9, 2016, Taro Pharmaceutical Industries Ltd. disclosed it and two of its senior officers received grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) declined from $145.20 per share in August 2016 to as low as $101.02 per share on October 20, 2016.